Targeted Covalent Inhibitors for the Treatment of Malaria? | Zendy

Shashank Kulkarni | Zendy; Klaus Urbahns | Zendy; Thomas Spangenberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeted Covalent Inhibitors for the Treatment of Malaria?

Author(s) -

Shashank Kulkarni,

Klaus Urbahns,

Thomas Spangenberg

Publication year - 2020

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.0c00684

Subject(s) - malaria , plasmodium falciparum , infectious disease (medical specialty) , antimalarial agent , disease , biology , medicine , immunology , pathology

Malaria is a vector-borne disease caused by protozoan parasites of the genus Plasmodium . According to the World Health Organization, it is one of the most serious infectious diseases threatening more than 3 billion people worldwide. In recent years, targeted covalent inhibitors (TCIs) have gained a lot of attention and several TCI-based drugs have been approved across different therapeutic areas. For malaria, surprisingly, this approach has not been explored in depth even though lot of advancements have been made in understanding the biology of the parasite. Herein, we present our views on exploring TCIs as a new class of antimalarial agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research